Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference…
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points…
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and…
--Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3…
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third…
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision…
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase…
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject…
New Data Detail Efficacy of HDAC6 Inhibition Compared to Empagliflozin in Model of Heart Failure with Preserved Ejection FractionSOUTH SAN…
- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression…